ETH Zurich Licenses DiscoveryGate®Content Platform
Premier chemical information resource from Elsevier MDL licensed by leading European research institution
San Ramon, CA – June 19, 2007 – Elsevier MDL is pleased to announce that ETH Zurich (Swiss Federal Institute of Technology) has licensed the full online DiscoveryGate® content platform. DiscoveryGate serves tens of thousands of scientists and researchers at more than 400 commercial, academic and government institutions worldwide and is supported on both the Microsoft Windows® and Apple Macintosh® OS X platforms. Hands-on experience with DiscoveryGate in academia prepares students for success in today's highly competitive job market, as the platform is widely deployed in the commercial research environment.
"DiscoveryGate enables chemistry researchers, staff and students alike, to access a very useful suite of chemistry databases and links to other scientific information," said Dr. Engelbert Zass, ETH Chemistry-Biology-Pharmacy Information Center. "The ability to access such comprehensive information anywhere on campus enables researchers to save time locating relevant materials and accelerates decision making."
"We are very pleased that ETH Zurich has adopted the DiscoveryGate platform," said Lars Barfod, President and CEO of Elsevier MDL. "ETH is one of the world’s leading research institutions with 21 affiliated Nobel Prize winners, including the 2002 Chemistry laureate, Dr. Kurt Wüthrich who was the keynote speaker at Elsevier MDL’s 2007 European User Group Meeting. DiscoveryGate is building a solid track record in academia by providing single-click access to a wealth of information that maps to laboratory workflows."
DiscoveryGate's unique integration and linking of content enables researchers to compare information and results that are not available through other systems. With the recent indexing of important new data sources such as the PharmaPendium™ drug safety resource, PubChem® database and the GeneGo systems biology/pathway analysis platform, DiscoveryGate now provides detailed scientific information on more than 27 million chemical compounds, 17 million reactions and 500 million observed chemical facts, including synthesis, bioactivity, metabolism, toxicology, physical property, chemical sourcing, pharmacology and patent data.
Researchers can access 17 databases including the Beilstein and Gmelin databases, MDL® Available Chemicals Directory, MDL® Drug Data Report, MDL® Toxicity Database and authoritative reference works on synthetic methodology. Researchers can also search compounds in PubChem and the Derwent World Patents Index® and link to over 20,000 journal titles (with additional licenses required to access certain third-party content).
DiscoveryGate's academic site-wide licenses grant simultaneous access to any number of researchers, avoiding the limitations of limited-user licenses. To learn more about how DiscoveryGate helps researchers find the information they need, visit www.discoverygate.com, contact your Elsevier MDL Account Manager or request information at www.mdl.com.
# # #
About Elsevier MDL
Elsevier MDL provides informatics, database and workflow solutions that accelerate successful scientific R&D by improving the speed and quality of scientists’ decision making. Researchers around the world depend on Elsevier MDL for innovative and reliable discovery informatics software solutions and services augmented by 400 Elsevier chemistry and life sciences journals and related products. For more information, visit www.mdl.com.
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. For more information, visit www.elsevier.com.
Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange). For more information, visit www.reedelsevier.com.About Elsevier
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Phone: +1 925 543-5400